Cancers, Vol. 16, Pages 1050: Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts
L. Levitt Jennifer L. Leiting Amro M. Abdelrahman Xinli Zhu Fabrice Lucien Mark J. Truty Lewis R. Roberts Upamostat is an orally available small-molecule serine protease inhibitor that is a highly potent inhibitor of trypsin 1, trypsin 2, trypsin 3 (PRSS1/2/3), and the urokinase-type plasminogen activator (uPA). These enzymes are expressed in many cancers, especially during tissue remodeling and subsequent tumor cell invasion. Opaganib (ABC294640), a novel, orally available small molecule is a selective inhibitor of the phosphorylation of sphingosine to sphingosine-1-phosphate (S-1-P) by sphingosine kinase...
Source: Cancers - March 5, 2024 Category: Cancer & Oncology Authors: Faizal Z. Asumda Nellie A. Campbell Mohamed A. Hassan Reza Fathi Daniella F. Vasquez Rico Melanie Kiem Ethan V. Vang Yo Han Kim Xin Luo Daniel R. O ’Brien Sarah A. Buhrow Joel M. Reid Michael J. Moore Vered Katz Ben-Yair Mark L. Levitt Jennifer L. Leiti Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1053: Chimeric Antigen Receptor-Modified T Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer: Promise and Potential
Gupta Prostate cancer, the most common cancer among males, has a mortality rate of approximately 29,000 deaths each year in the United States alone [...] (Source: Cancers)
Source: Cancers - March 5, 2024 Category: Cancer & Oncology Authors: Leah R. Tharian Shiv Verma Sanjay Gupta Tags: Editorial Source Type: research

Cancers, Vol. 16, Pages 1054: Advancements in the Treatment Landscape of Hepatocellular Carcinoma
a The landscape of hepatocellular carcinoma (HCC) treatment has expanded significantly with the advent of multi-kinase inhibitors and immune checkpoint inhibitors [...] (Source: Cancers)
Source: Cancers - March 5, 2024 Category: Cancer & Oncology Authors: Takefumi Kimura Tags: Editorial Source Type: research

Cancers, Vol. 16, Pages 1052: Impact of Primary Tumor Location on Demographics, Resectability, Outcomes, and Quality of Life in Finnish Metastatic Colorectal Cancer Patients (Subgroup Analysis of the RAXO Study)
Aki Uutela Tapio Salminen Hanna Stedt Annamarja Lamminmäki Timo Muhonen Juha Kononen Bengt Glimelius Helena Isoniemi Juho T. Lehto Kaisa Lehtomäki Pia Osterlund The primary tumor location (PTL) is associated with the phenotype, metastatic sites, mutations, and outcomes of metastatic colorectal cancer (mCRC) patients, but this has mostly been studied according to sidedness (right vs. left sided). We studied right colon vs. left colon vs. rectal PTL in a real-life study population (n = 1080). Health-related quality of life (HRQoL) was assessed multi-cross-sectionally with QLQ-C30, QLQ-CR29, EQ-5D, a...
Source: Cancers - March 5, 2024 Category: Cancer & Oncology Authors: Sonja Aho Emerik Osterlund Ari Ristim äki Lasse Nieminen Jari Sundstr öm Markus J. M äkinen Teijo Kuopio Soili Kyt ölä Annika Ålgars Raija Ristam äki Eetu Heerv ä Raija Kallio P äivi Halonen Leena-Maija Soveri Arno Nordin Aki Uutela Tapio Salmine Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1051: Study International Multicentric Pancreatic Left Resections (SIMPLR): Does Surgical Approach Matter?
Conclusion: The laparoscopic approach exhibits short-term benefits. The three techniques are equivalent in terms of oncological safety, morbidity, and mortality. (Source: Cancers)
Source: Cancers - March 5, 2024 Category: Cancer & Oncology Authors: Sara Acciuffi Mohammed Abu Hilal Clarissa Ferrari Sara Al-Madhi Marc-Anthony Chouillard Nouredin Messaoudi Roland S. Croner Andrew A. Gumbs Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1055: Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients
Conclusions: In the treatment of mild-to-moderate COVID-19 in cancer patients, Molnupiravir was comparable to Nirmatrelvir/Ritonavir in preventing progression to severe disease/death and rebound events, and it had a superior safety profile. (Source: Cancers)
Source: Cancers - March 5, 2024 Category: Cancer & Oncology Authors: Andrea J. Haddad Ray Y. Hachem Mohamed Moussa Ying Jiang Hiba R. Dagher Patrick Chaftari Anne-Marie Chaftari Issam I. Raad Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1056: Pancreatic Cancer Treatment Targeting the HGF/c-MET Pathway: The MEK Inhibitor Trametinib
Woo Hyun Paik Pancreatic cancer is characterized by fibrosis/desmoplasia in the tumor microenvironment, which is primarily mediated by pancreatic stellate cells and cancer-associated fibroblasts. HGF/c-MET signaling, which is instrumental in embryonic development and wound healing, is also implicated for its mitogenic and motogenic properties. In pancreatic cancer, this pathway, along with its downstream signaling pathways, is associated with disease progression, prognosis, metastasis, chemoresistance, and other tumor-related factors. Other features of the microenvironment in pancreatic cancer with the HGF/c-MET path...
Source: Cancers - March 5, 2024 Category: Cancer & Oncology Authors: Junyeol Kim Tae Seung Lee Myeong Hwan Lee In Rae Cho Ji Kon Ryu Yong-Tae Kim Sang Hyub Lee Woo Hyun Paik Tags: Review Source Type: research

Cancers, Vol. 16, Pages 1057: Glutamine Supplementation as an Anticancer Strategy: A Potential Therapeutic Alternative to the Convention
ck Jun Gong Glutamine, a multifaceted nonessential/conditionally essential amino acid integral to cellular metabolism and immune function, holds pivotal importance in the landscape of cancer therapy. This review delves into the intricate dynamics surrounding both glutamine antagonism strategies and glutamine supplementation within the context of cancer treatment, emphasizing the critical role of glutamine metabolism in cancer progression and therapy. Glutamine antagonism, aiming to disrupt tumor growth by targeting critical metabolic pathways, is challenged by the adaptive nature of cancer cells and the complex metab...
Source: Cancers - March 5, 2024 Category: Cancer & Oncology Authors: Hayato Muranaka Rasaq Akinsola Sandrine Billet Stephen J. Pandol Andrew E. Hendifar Neil A. Bhowmick Jun Gong Tags: Review Source Type: research

Cancers, Vol. 16, Pages 1058: Immunotherapy and Radiation Therapy Combinatorial Approaches in Hepatocellular Carcinoma
This article delves into the promising approach of combining immunotherapy, particularly immune checkpoint inhibitors, with radiation therapy, a cornerstone of HCC management. Our review synthesizes current preclinical and clinical research, highlighting the potential synergistic effects of this combinational treatment. Emerging evidence suggests that this synergy enhances tumor control and improves patient survival rates. The combination leverages the localized, tumor-targeting ability of radiation therapy and the systemic, immune-boosting effects of immunotherapy, potentially overcoming the limitations inherent in each t...
Source: Cancers - March 5, 2024 Category: Cancer & Oncology Authors: Alireza Tojjari James Yu Anwaar Saeed Tags: Review Source Type: research

Cancers, Vol. 16, Pages 1059: Dynamic Survival Risk Prognostic Model and Genomic Landscape for Atypical Teratoid/Rhabdoid Tumors: A Population-Based, Real-World Study
Conclusions: In this study, we devised a predictive model that effectively gauges the prognosis of AT/RT and briefly analyzed its genomic features, which might offer a valuable tool to address existing clinical challenges. (Source: Cancers)
Source: Cancers - March 5, 2024 Category: Cancer & Oncology Authors: Sihao Chen Yi He Jiao Liu Ruixin Wu Menglei Wang Aishun Jin Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1048: Increased O-GlcNAcylation by Upregulation of Mitochondrial O-GlcNAc Transferase (mOGT) Inhibits the Activity of Respiratory Chain Complexes and Controls Cellular Bioenergetics
Krześlak O-linked β-N-acetylglucosamine (O-GlcNAc) is a reversible post-translational modification involved in the regulation of cytosolic, nuclear, and mitochondrial proteins. The interplay between O-GlcNAcylation and phosphorylation is critical to control signaling pathways and maintain cellular homeostasis. The addition of O-GlcNAc moieties to target proteins is catalyzed by O-linked N-acetylglucosamine transferase (OGT). Of the three splice variants of OGT described, one is destined for the mitochondria (mOGT). Although the effects of O-GlcNAcylation on the biology of normal and cancer cells are well ...
Source: Cancers - March 5, 2024 Category: Cancer & Oncology Authors: Pawe ł Jóźwiak Joanna Oracz Angela Dziedzic Rafa ł Szelenberger Dorota Żyżelewicz Micha ł Bijak Anna Krze ślak Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1041: Dual Checkpoint Aptamer Immunotherapy: Unveiling Tailored Cancer Treatment Targeting CTLA-4 and NKG2A
This study employs a computational biology tool (in silico approach) to craft aptamers capable of binding to dual receptors, namely, inhibitory CTLA4 and NKG2A, thereby unleashing both T and NK cells and enhancing CD8+ T and NK cell functions for tumor cell lysis. Computational analysis highlighted AYA22T-R2-13 with HADDOCK scores of −78.2 ± 10.2 (with CTLA4), −60.0 ± 4.2 (with NKG2A), and −77.5 ± 5.6 (with CD94/NKG2A). Confirmation of aptamer binding to targeted proteins was attained via ELISA and flow cytometry methods. In vitro biolog...
Source: Cancers - March 4, 2024 Category: Cancer & Oncology Authors: Mohamad Ammar Ayass Trivendra Tripathi Natalya Griko Tutku Okyay Ramya Ramankutty Nair Jin Zhang Kevin Zhu Kristen Melendez Victor Pashkov Lina Abi-Mosleh Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1042: Soft Tissue Sarcomas: Treatment and Management
chiya Due to the rarity and heterogeneity of soft tissue sarcoma (STS), investigating new treatments for this condition has been challenging [...] (Source: Cancers)
Source: Cancers - March 4, 2024 Category: Cancer & Oncology Authors: Shinji Miwa Po-Kuei Wu Hiroyuki Tsuchiya Tags: Editorial Source Type: research

Cancers, Vol. 16, Pages 1043: Impact of Pre-Liver Transplant Treatments on the Imaging Accuracy of HCC Staging and Their Influence on Outcomes
In conclusion, the concordance rate between the pre-LT imaging and histopathological results was low in patients with a high number of nodules. Multiple bridging therapies reduce the accuracy of pre-LT imaging in predicting HCC stages and negatively affect outcomes after LT. (Source: Cancers)
Source: Cancers - March 4, 2024 Category: Cancer & Oncology Authors: Eloisa Franchi Daniele Eliseo Dondossola Giulia Maria Francesca Marini Massimo Iavarone Luca Del Prete Clara Di Benedetto Maria Francesca Donato Barbara Antonelli Pietro Lampertico Lucio Caccamo Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1044: The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Cutaneous Oncology: A Systematic Review of Evidence beyond Malignant Melanoma
Bassukas With the ongoing progress of basic research along with the introduction of new pharmaceutical options spanning almost all therapeutic areas, the need for biomarkers that will be implemented into the personalized medical approach is higher than ever. Their use can be incorporated into clinical practice and can be applied to the classification of disorders and the evaluation of disease severity but also to the monitoring of the progress of therapeutic/pharmaceutical interventions. This systematic review collects the findings of hematologic biomarkers in various cutaneous malignancies, excluding malignant melan...
Source: Cancers - March 4, 2024 Category: Cancer & Oncology Authors: Seretis Sfaelos Boptsi Gaitanis Bassukas Tags: Systematic Review Source Type: research